Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Bone Marrow Transplant. 2020 Dec 1;56(5):1090–1098. doi: 10.1038/s41409-020-01149-x

Figure 1. Maternal microchimerism of the cord blood donor (CB-MMc) in patients who received double or single CB transplantation (CBT).

Figure 1.

CB-MMc concentrations are measured in human cell genome equivalent (gEq) of CB-MMc DNA per million gEq of total DNA tested from bone marrow aspirates (BMA), whole peripheral blood (WB), neutrophils, peripheral blood mononuclear cells (PBMC), T, B, NK cells, and monocytes; those last four subsets are tested only if a positive CB-MMc has been detected in BMA, WB, neutrophils, or PBMCs at any timepoint. CB-MMc assays targeted the CB non-shared, non-inherited maternal HLA allele (NIMA) of the winning and/or losing CB units in case of double CBT, or the single unit in case of single CBT. Blank spots are when a specimen at a timepoint was not available or a CB-NIMA-specific assay was not available for testing. Timepoints were grouped into 4 classes, and events of death or relapse are shown. *Patients 048, 108, 018, 073, 098, 112, and 122 were single CBT recipients (i.e. no losing unit), and 029 and 088 had a CBT engraftment that remained mixed (i.e. no winning or losing). n/d= not detected